<DOC>
	<DOCNO>NCT00156897</DOCNO>
	<brief_summary>The purpose study investigate whether ATL-962 induces weight loss diabetic patient whether safety tolerability profile superior orlistat patient</brief_summary>
	<brief_title>Efficacy Safety ATL-962 Obese Diabetics</brief_title>
	<detailed_description>Obesity significant increase clinical problem . There need effective therapeutic agent help people reduce weight . ATL-962 lipase inhibitor could reduce amount fat absorb person 's diet , lead weight reduction . In study patient Type II diabetes clinically obese receive ATL-962 one three dose level , placebo , orlistat ( another lipase inhibitor ) . The study investigate amount weight lost 12 week ' treatment compare safety tolerability profile ATL-962 orlistat .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Orlistat</mesh_term>
	<criteria>Type II diabetes Body mass index 2845kg/m2 HbA1c 6 % 10 % Significant weight loss previous 3 month Weight gain runin period Other serious systemic condition , except control hypertension , mild asthma , primary hypothyroidism History GI disorder Previous surgery weight loss</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2006</verification_date>
	<keyword>Non-insulin-dependent diabetes mellitus</keyword>
	<keyword>NIDDM</keyword>
	<keyword>Type II diabetes</keyword>
	<keyword>Obesity</keyword>
	<keyword>Lipase inhibitor</keyword>
</DOC>